Every round on record, with the sources behind each and the investors on them.
Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus.
corxelbio.comBiotech
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The company’s release says the financing raised “up to $287 million”; no separate financing total or valuation is stated. The Berkeley Heights dateline does not establish headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series D+ Series D1 financing [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $287M | 2026-01-22 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The company’s release says the financing raised “up to $287 million”; no separate financing total or valuation is stated. The Berkeley Heights dateline does not establish headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: globenewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage | ||||